Results 131 to 140 of about 8,937 (232)

Activation of TREK‐1 and TREK‐2 Two‐Pore Domain Potassium Channels by the Kv4 Channel Modulator, NS5806

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT NS5806 is a diaryl‐urea small molecule developed for the treatment of pain and neurological disorders. A potent activator of Kv4.3 potassium channels, it is widely used to study Kv4 channel physiology in excitable cells, including trigeminal neurons.
E. L. Veale   +4 more
wiley   +1 more source

Microglial Activation Under Hypoxic Conditions in Early Alzheimer's Disease: Can Natural SIRT1 Activators Be Therapeutic Allies in the Inflammation–Energy Axis?

open access: yesPhytotherapy Research, Volume 40, Issue 6, Page 3354-3368, June 2026.
ABSTRACT Alzheimer's disease (AD) is a progressive neurodegenerative condition characterized by a preclinical stage that typically lasts for decades. Early on during this time, microglia react to pathological changes and become protective and even transiently delay neurodegeneration.
Sara Merlo   +3 more
wiley   +1 more source

Effect of chilled eye drops on postoperative pain sensation after phototherapeutic keratectomy: Randomised controlled clinical trial

open access: yesActa Ophthalmologica, Volume 104, Issue 4, Page 438-447, June 2026.
Abstract Purpose To analyse pain sensation after phototherapeutic keratectomy (PTK) using chilled eye drops or drops at room temperature during the early postoperative period. Methods Our randomised controlled, parallel‐group study conducted in the Department of Ophthalmology, Goethe‐University, Frankfurt (Main), Germany, with blinded participants and ...
Carolin Marion Kolb‐Wetterau   +7 more
wiley   +1 more source

Cerebrospinal Fluid and Plasma Concentrations of Atogepant in Humans

open access: yesClinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT The aim of this study was to determine the cerebrospinal fluid (CSF) to plasma concentration ratio of atogepant. Healthy adult participants (N = 28) were enrolled into this phase 1, open‐label study and received atogepant 60 mg once daily for 8 days. Steady‐state atogepant concentrations were determined from CSF samples collected on Day 6 at 2
Ramesh R. Boinpally, Joel M. Trugman
wiley   +1 more source

HCN2 channels: a potential therapeutic target for orofacial neuropathic pain after trigeminal nerve injury. [PDF]

open access: yesJ Oral Facial Pain Headache
Yamamoto T   +6 more
europepmc   +1 more source

Efficacy, IHS Guideline Adherence, and Methodological Quality of Noninvasive Neuromodulation Clinical Trials in Migraine and Cluster Headache: A Systematic Review

open access: yesEuropean Journal of Neurology, Volume 33, Issue 6, June 2026.
ABSTRACT Background Noninvasive neuromodulation has emerged as a promising approach for acute and preventive treatment of migraine and cluster headache. This systematic review evaluates how noninvasive neuromodulation trials align with guidelines by the International Headache Society (IHS), their efficacy on IHS‐recommended outcomes, and the robustness
Javiera Canales‐Rodríguez   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy